BRPI0610514A2 - composto, composição farmacêutica, e, método de tratamento de um distúrbio - Google Patents
composto, composição farmacêutica, e, método de tratamento de um distúrbioInfo
- Publication number
- BRPI0610514A2 BRPI0610514A2 BRPI0610514A BRPI0610514A BRPI0610514A2 BR PI0610514 A2 BRPI0610514 A2 BR PI0610514A2 BR PI0610514 A BRPI0610514 A BR PI0610514A BR PI0610514 A BRPI0610514 A BR PI0610514A BR PI0610514 A2 BRPI0610514 A2 BR PI0610514A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- treating
- compound
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66828605P | 2005-04-05 | 2005-04-05 | |
| US73666305P | 2005-11-15 | 2005-11-15 | |
| PCT/US2006/012824 WO2006108103A1 (en) | 2005-04-05 | 2006-04-05 | Purine and imidazopyridine derivatives for immunosuppression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0610514A2 true BRPI0610514A2 (pt) | 2016-11-16 |
Family
ID=36699182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0610514A BRPI0610514A2 (pt) | 2005-04-05 | 2006-04-05 | composto, composição farmacêutica, e, método de tratamento de um distúrbio |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070021443A1 (pt) |
| EP (1) | EP1874772A1 (pt) |
| JP (1) | JP2008534689A (pt) |
| KR (1) | KR20080013886A (pt) |
| AU (1) | AU2006232105A1 (pt) |
| BR (1) | BRPI0610514A2 (pt) |
| CA (1) | CA2604161A1 (pt) |
| IL (1) | IL186451A0 (pt) |
| MX (1) | MX2007012393A (pt) |
| NO (1) | NO20075560L (pt) |
| NZ (1) | NZ562468A (pt) |
| RU (1) | RU2007140903A (pt) |
| WO (1) | WO2006108103A1 (pt) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US20070225304A1 (en) * | 2005-09-06 | 2007-09-27 | Pharmacopeia Drug Discovery, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| WO2007035873A1 (en) * | 2005-09-21 | 2007-03-29 | Pharmacopeia, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| US20070253896A1 (en) * | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| KR20080107466A (ko) * | 2006-03-09 | 2008-12-10 | 파마코페이아, 인코포레이티드 | 대사 장애 치료용 8-헤테로아릴퓨린 ｍｎｋ2 억제제 |
| CL2007002593A1 (es) * | 2006-09-07 | 2008-06-13 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer. |
| CL2007002866A1 (es) | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
| US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| CL2007002867A1 (es) * | 2006-10-04 | 2008-06-27 | Pharmacopeia Inc | Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras. |
| US7981893B2 (en) * | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| KR20100014271A (ko) * | 2006-11-16 | 2010-02-10 | 파마코페이아, 엘엘씨. | 면역 억제를 위한 7-치환된 퓨린 유도체 |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| JP2010521450A (ja) * | 2007-03-16 | 2010-06-24 | アクテリオン ファーマシューティカルズ リミテッド | Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体 |
| CN101679412A (zh) | 2007-05-23 | 2010-03-24 | 药典有限责任公司 | 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类 |
| HUE029236T2 (en) | 2007-06-13 | 2017-02-28 | Incyte Holdings Corp | (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor |
| CA2691914C (en) * | 2007-07-11 | 2012-06-26 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| WO2009048474A1 (en) * | 2007-10-12 | 2009-04-16 | Pharmacopeia, Inc. | 2,7,9-substituted purinone derivatives for immunosuppression |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| EP2262799B1 (en) * | 2008-03-06 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Pyridine compounds |
| SI2252609T1 (sl) * | 2008-03-07 | 2013-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-2-ila kot imunomodulacijska sredstva |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| JP5731978B2 (ja) * | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| WO2010045276A2 (en) * | 2008-10-16 | 2010-04-22 | Cara Therapeutics, Inc. | Azabenzimidazolones |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| AU2009320683B2 (en) | 2008-11-28 | 2012-07-19 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP2432472B1 (en) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| KR101409131B1 (ko) | 2009-07-16 | 2014-06-17 | 액테리온 파마슈티칼 리미티드 | 피리딘-4-일 유도체 |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SG179206A1 (en) | 2009-09-25 | 2012-04-27 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| NZ618135A (en) | 2009-10-26 | 2015-05-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| SI2493895T1 (sl) * | 2009-10-29 | 2017-10-30 | Vectura Limited | Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| WO2011096490A1 (ja) * | 2010-02-04 | 2011-08-11 | 第一三共株式会社 | イミダゾピリジン－２－オン誘導体 |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| AR084691A1 (es) | 2010-05-21 | 2013-06-05 | Incyte Corp | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| CA2803448A1 (en) * | 2010-07-06 | 2012-01-12 | Universite De Montreal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| SG191742A1 (en) | 2011-01-19 | 2013-08-30 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ | 新規のピリミジン誘導体 |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013025628A1 (en) | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
| US9403829B2 (en) | 2011-12-02 | 2016-08-02 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| JP6114317B2 (ja) | 2012-02-24 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法 |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| TWI761825B (zh) | 2012-11-15 | 2022-04-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| MX2015009209A (es) | 2013-01-16 | 2016-03-17 | Signal Pharm Llc | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. |
| MX384910B (es) | 2013-03-06 | 2025-03-14 | Incyte Holdings Corp | Procesos e intermedios para hacer un inhibidor de jak. |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
| AU2014254059B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer |
| HK1223286A1 (zh) | 2013-05-29 | 2017-07-28 | 西格诺药品有限公司 | 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法 |
| SG11201600815WA (en) | 2013-08-07 | 2016-03-30 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US10386994B2 (en) * | 2015-02-17 | 2019-08-20 | Microsoft Technology Licensing, Llc | Control of item arrangement in a user interface |
| MY192358A (en) | 2015-05-20 | 2022-08-17 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| WO2017133657A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| MX2019000982A (es) * | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
| ES2959860T3 (es) | 2017-06-22 | 2024-02-28 | Celgene Corp | Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B |
| BR112020006599B1 (pt) * | 2017-10-04 | 2024-02-20 | Celgene Corporation | Cápsulas compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricl oroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carb oxamida |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| JP7393348B2 (ja) | 2018-01-30 | 2023-12-06 | インサイト・コーポレイション | （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体 |
| CN113768934A (zh) | 2018-03-30 | 2021-12-10 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| WO2021032004A1 (zh) | 2019-08-22 | 2021-02-25 | 上海青煜医药科技有限公司 | 氮杂芳基化合物及其应用 |
| CN114302887B (zh) * | 2019-09-05 | 2025-04-15 | 伯尔尼大学 | 三环Janus激酶(JAK)抑制剂及其在治疗自身免疫性疾病中的用途 |
| KR102316961B1 (ko) | 2020-01-29 | 2021-10-26 | 프라비바이오 주식회사 | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| KR20220120065A (ko) | 2021-02-22 | 2022-08-30 | 프라비바이오 주식회사 | 항암제로서의 벤젠 유도체의 용도 |
| CN113307765A (zh) * | 2021-05-24 | 2021-08-27 | 上海泰坦科技股份有限公司 | 吡啶甲胺类化合物及其制备方法 |
| US20240408072A1 (en) * | 2021-10-27 | 2024-12-12 | Esgelbio Inc. | Composition for preventing or treating graves' disease comprising compound containing an imidazopyridine structure as active ingredient |
| CN115433153B (zh) * | 2022-06-13 | 2023-11-28 | 大连大学 | 一对具有抗炎活性的聚酮类化合物及其制备方法和应用 |
| CN116574047A (zh) * | 2023-05-17 | 2023-08-11 | 杭州新曦科技有限公司 | 一种制备阿托伐他汀钙的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4813998A (en) * | 1986-02-27 | 1989-03-21 | Janssen Pharmaceutica N.V. | Herbicidal 1H-imidazole-5-carboxylic acid derivatives |
| FR2643903A1 (fr) * | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| DE4007535A1 (de) * | 1990-03-09 | 1991-09-12 | Hoechst Ag | Wasserunloesliche azofarbmittel, ihre herstellung und verwendung |
| US5705625A (en) * | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
| US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| ZA9810490B (en) * | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| EP1105378B1 (en) * | 1998-08-21 | 2005-03-30 | Parker Hughes Institute | Quinazoline derivatives |
| EP1109555A4 (en) * | 1998-08-31 | 2001-11-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| US6582357B2 (en) * | 2000-05-24 | 2003-06-24 | Pentax Corporation | Treating instrument erecting device for use in endoscope |
| US6504738B2 (en) * | 2000-12-14 | 2003-01-07 | Illinois Tool Works | Freewheeling current conduction in welding power supply |
| AR035230A1 (es) * | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
| CA2486187C (en) * | 2002-05-23 | 2013-02-19 | Cytopia Pty Ltd. | Kinase inhibitors |
| AU2003282550C1 (en) * | 2002-10-09 | 2008-09-25 | Tolerx, Inc. | Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use |
| AU2003276591A1 (en) * | 2002-11-26 | 2004-06-18 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| KR101224300B1 (ko) * | 2003-02-05 | 2013-01-21 | 바이엘 크롭사이언스 아게 | 키랄 바이사이클릭 라디칼로 ｎ-치환된 아미노 １,３,５-트라이아진, 이것의 제조방법, 이것의 조성물 및 제초제 및 식물 성장 조절제로서의 이것의 용도 |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| WO2004113322A1 (en) * | 2003-06-24 | 2004-12-29 | Pfizer Products Inc. | Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives |
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| WO2007035873A1 (en) * | 2005-09-21 | 2007-03-29 | Pharmacopeia, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| CL2007002866A1 (es) * | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
| CL2007002867A1 (es) * | 2006-10-04 | 2008-06-27 | Pharmacopeia Inc | Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras. |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| JP5313883B2 (ja) * | 2007-04-18 | 2013-10-09 | キッセイ薬品工業株式会社 | 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途 |
| WO2010018131A1 (en) * | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
-
2006
- 2006-04-05 WO PCT/US2006/012824 patent/WO2006108103A1/en not_active Ceased
- 2006-04-05 BR BRPI0610514A patent/BRPI0610514A2/pt not_active IP Right Cessation
- 2006-04-05 AU AU2006232105A patent/AU2006232105A1/en not_active Abandoned
- 2006-04-05 US US11/398,357 patent/US20070021443A1/en not_active Abandoned
- 2006-04-05 KR KR1020077025666A patent/KR20080013886A/ko not_active Withdrawn
- 2006-04-05 CA CA002604161A patent/CA2604161A1/en not_active Abandoned
- 2006-04-05 NZ NZ562468A patent/NZ562468A/en not_active IP Right Cessation
- 2006-04-05 MX MX2007012393A patent/MX2007012393A/es active IP Right Grant
- 2006-04-05 JP JP2008505516A patent/JP2008534689A/ja active Pending
- 2006-04-05 EP EP06740614A patent/EP1874772A1/en not_active Withdrawn
- 2006-04-05 RU RU2007140903/04A patent/RU2007140903A/ru not_active Application Discontinuation
-
2007
- 2007-10-07 IL IL186451A patent/IL186451A0/en unknown
- 2007-11-02 NO NO20075560A patent/NO20075560L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20075560L (no) | 2007-12-20 |
| NZ562468A (en) | 2009-10-30 |
| US20070021443A1 (en) | 2007-01-25 |
| EP1874772A1 (en) | 2008-01-09 |
| MX2007012393A (es) | 2008-02-22 |
| KR20080013886A (ko) | 2008-02-13 |
| RU2007140903A (ru) | 2009-05-20 |
| JP2008534689A (ja) | 2008-08-28 |
| WO2006108103A1 (en) | 2006-10-12 |
| AU2006232105A1 (en) | 2006-10-12 |
| CA2604161A1 (en) | 2006-10-12 |
| IL186451A0 (en) | 2008-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0514094A (pt) | composto, composição, e, método de tratamento de distúrbio hiperproliferativo | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| BRPI0820474A2 (pt) | método de tratamento de uma doença, uso de composto, e, composto | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0810354A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor | |
| BRPI0915267A2 (pt) | Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| BRPI0820568A2 (pt) | Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal | |
| BRPI0717753A2 (pt) | Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição. | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| EP2429987A4 (en) | AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| BRPI0814300A2 (pt) | Composto, composição farmacêutica, e, método para tratar uma infecção viral | |
| BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
| BRPI0914371A2 (pt) | "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação" | |
| BRPI0908883A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0923856A2 (pt) | composto, composição farmacêutica, uso de um composto, e método para tratar uma doença ou distúrbio. | |
| FI20040011L (fi) | Menetelmä pintojen käsittelemiseksi | |
| BRPI0607748A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um distúrbio | |
| BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 20070140601/RJ DE 04/10/2007. |
|
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0 |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0 |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |